Mehdi Dehghani1, Negar Azarpira2, Vahid Mohammad Karimi3, Hamid Mossayebi3, Elaheh Esfandiari2. 1. Hematology & Oncology Department of Internal Medicine, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Transplant Research Center, Shiraz Institute for Stem Cell and Regenerative Medicine, Shiraz University of Medical Science, Shiraz, Iran. 3. Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
OBJECTIVE: To compare the healing process of pressure ulcers treated with cryopreserved human amniotic membrane allograft and routine pressure ulcer care in our hospital. METHODS: From January 2012 to December 2013, in a prospective randomized clinical trial (IRCT201612041335N2), 24 patients with second and third stage of pressure ulcers were enrolled in this study. All patients needed split-thickness skin grafts for pressure ulcer-wound coverage. Selected patients had symmetric ulcers on both upper and lower extremities. The patients were randomly divided into two groups: amnion and control. In the amnion group, the ulcer was covered with cryopreserved amniotic membrane and in the control group it was treated with local Dilantin powder application. The duration and success rate of complete healing was compared between the two groups. RESULTS: The study group was composed of 24 pressure ulcers in 24 patients (19 males and 5 females) with a mean age of 44±12.70 years. The demographic characteristics, ulcer area, and underlying diseases were similar in both groups. The early sign of response, such as decrease in wound discharge, was detected 12-14 days after biological dressing. Complete pressure ulcer healing occurred only in the amnion group (p< 0.001). Partial healing was significantly higher in the amnion group (p< 0.03). Healing time in this group was faster than that the control group (20 days versus 54 days). No major complication was recorded with amniotic membrane dressing. CONCLUSION: Cryopreserved amniotic membrane is an effective biologic dressing that promotes re-epithelialization in pressure ulcers.
OBJECTIVE: To compare the healing process of pressure ulcers treated with cryopreserved human amniotic membrane allograft and routine pressure ulcer care in our hospital. METHODS: From January 2012 to December 2013, in a prospective randomized clinical trial (IRCT201612041335N2), 24 patients with second and third stage of pressure ulcers were enrolled in this study. All patients needed split-thickness skin grafts for pressure ulcer-wound coverage. Selected patients had symmetric ulcers on both upper and lower extremities. The patients were randomly divided into two groups: amnion and control. In the amnion group, the ulcer was covered with cryopreserved amniotic membrane and in the control group it was treated with local Dilantin powder application. The duration and success rate of complete healing was compared between the two groups. RESULTS: The study group was composed of 24 pressure ulcers in 24 patients (19 males and 5 females) with a mean age of 44±12.70 years. The demographic characteristics, ulcer area, and underlying diseases were similar in both groups. The early sign of response, such as decrease in wound discharge, was detected 12-14 days after biological dressing. Complete pressure ulcer healing occurred only in the amnion group (p< 0.001). Partial healing was significantly higher in the amnion group (p< 0.03). Healing time in this group was faster than that the control group (20 days versus 54 days). No major complication was recorded with amniotic membrane dressing. CONCLUSION: Cryopreserved amniotic membrane is an effective biologic dressing that promotes re-epithelialization in pressure ulcers.
Authors: Tom Defloor; Michael Clark; Anne Witherow; Denis Colin; Christina Lindholm; Lisette Schoonhoven; Zena Moore Journal: J Tissue Viability Date: 2005-08 Impact factor: 2.932
Authors: Monika Kuck; Helene Strese; Seyed Arash Alawi; Martina C Meinke; Joachim W Fluhr; Guido J Burbach; Martin Krah; Wolfram Sterry; Jürgen Lademann Journal: Skin Res Technol Date: 2013-06-19 Impact factor: 2.365
Authors: Alzbeta Svobodova; Vojtech Horvath; Ingrida Smeringaiova; Joao Victor Cabral; Martina Zemlickova; Radovan Fiala; Jan Burkert; Denisa Nemetova; Petr Stadler; Jaroslav Lindner; Jan Bednar; Katerina Jirsova Journal: Int Wound J Date: 2021-11-17 Impact factor: 3.099
Authors: Sandeep Dhall; Malathi Sathyamoorthy; Jin-Qiang Kuang; Tyler Hoffman; Matthew Moorman; Anne Lerch; Vimal Jacob; Steven Michael Sinclair; Alla Danilkovitch Journal: PLoS One Date: 2018-10-02 Impact factor: 3.240